Our team is dedicated to protecting cognitive health across the lifespan. We pioneer population-based research identifying modifiable risk factors for dementia and cognitive aging, including their biological connections, to develop prevention strategies.
Published in The Lancet, our new research shows that midlife plasma biomarkers (Aβ42, Aβ40, and p-tau217) are associated with accelerated cognitive decline. These findings indicate that blood tests may offer a means of early detection for potential AD.
